uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies — Stella

Recruiting

Back to Acute Myeloid Leukemia (AML) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Early testing

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~12 participants

Started

June 2025

Primary completion

June 2028

Age range

18 Years – 70 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov